Stage IV Colorectal Cancer Clinical Trial
Official title:
High Definition Single Cell Analysis in Colorectal Cancer
Verified date | August 2023 |
Source | University of Southern California |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This research clinical trial studies high definition single cell analysis in blood and tissue samples from patients with colorectal cancer which has spread to the liver. High definition single cell analysis allows doctors to study the properties of cancer cells that are sometimes found in the blood of patients and to determine how the genes and proteins in them may change over time. Studying samples from patients with colorectal cancer in the laboratory may help doctors learn more about how cancer spreads, as well as how to predict the disease outcomes in patients with cancer.
Status | Completed |
Enrollment | 24 |
Est. completion date | May 29, 2020 |
Est. primary completion date | May 29, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Able to provide informed consent - Metastatic colorectal adenocarcinoma to the liver (hepatic mCRC) - Synchronous or metachronous - Solitary or multifocal - Concurrent abdominal lymph node metastasis is allowable - Hepatic mCRC deemed surgically resectable by the study team with plans to undergo surgery - Has not received any systemic chemotherapy for at least 21 days prior to scheduled hepatic resection Exclusion Criteria: - Non-adenocarcinoma metastatic colorectal cancer (e.g. neuroendocrine carcinoma); mucinous component is permitted - Metastatic CRC that involves organ(s)/tissue(s) other than abdominal lymph nodes and/or liver - Has received any systemic chemotherapy within 21 days prior to scheduled hepatic resection |
Country | Name | City | State |
---|---|---|---|
United States | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston | Texas |
United States | Scripps Cancer Center | La Jolla | California |
United States | Los Angeles County-USC Medical Center | Los Angeles | California |
United States | USC / Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Hoag Memorial Hospital Presbyterian | Newport Beach | California |
United States | USC Norris Oncology/Hematology-Newport Beach | Newport Beach | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HD-SCA liquid biopsy biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles | Biosignatures will be compared between cells from tumor tissue within the same patient, cells from blood samples within the same patient, cells from tumor tissue and blood samples within the same patient, cells from tumor tissue and blood samples across different patients. Upon these comparisons, biosignatures will be established which represent liquid and solid biopsy correlations for each patient and for the patient population. Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and acr | Up to 2 years | |
Primary | HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles | Biosignatures will be compared between cells from tumor tissue within the same patient, cells from blood samples within the same patient, cells from tumor tissue and blood samples within the same patient, cells from tumor tissue and blood samples across different patients. Upon these comparisons, biosignatures will be established which represent liquid and solid biopsy correlations for each patient and for the patient population. Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and acr | Up to 2 years | |
Secondary | HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles | The technical validity and reproducibility of the biosignatures will be demonstrated by comparing two pre-resection liquid biopsy samples. This reflects a change in the timing of specimen collection from the original protocol. Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and across patients. | Up to day 1 of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01704703 -
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
|
Phase 2 | |
Terminated |
NCT02960282 -
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
|
||
Completed |
NCT01998152 -
Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)
|
N/A | |
Not yet recruiting |
NCT06287723 -
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
|
||
Completed |
NCT03005002 -
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
|
Phase 1 | |
Completed |
NCT03095781 -
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
|
Phase 1 | |
Terminated |
NCT03111823 -
Exercise Program During Chemotherapy in Metastatic Colorectal Cancer
|
N/A | |
Active, not recruiting |
NCT04267575 -
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
|
N/A | |
Recruiting |
NCT03368963 -
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Active, not recruiting |
NCT01271582 -
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
|
Phase 4 | |
Active, not recruiting |
NCT03800602 -
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
Terminated |
NCT01550510 -
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
|
Phase 1/Phase 2 | |
Recruiting |
NCT02919644 -
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
|
Phase 2 | |
Completed |
NCT03373188 -
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT04044430 -
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT05025748 -
Ask Questions (ASQ):Implementation of a Communication Intervention
|
N/A | |
Completed |
NCT01722903 -
Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer
|
N/A |